Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay
Oncotarget · 2025
DOI: 10.18632/oncotarget.28761 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Oncotarget, 2025. Verfasst von Valeriy Domenyuk und 32 weiteren Autor:innen. Beteiligte Einrichtung: Caris Life Sciences, Irving, TX 75039, USA. Hauptthemen laut MEDLINE: Neoplasms, Gene Expression Profiling, Biomarkers, Tumor, Exome Sequencing. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The precision oncology industry has evolved rapidly within the past two decades, although treatment selection remains a complex undertaking. Access to timely, accurate, and comprehensive molecular profiling data is imperative to improving patient outcomes within the expanding sphere of Food and Drug Administration (FDA)-approved targeted therapies. Caris Life Sciences has developed MI Cancer Seek®, an FDA-approved whole exome and whole transcriptome sequencing-based molecular test encompassing adult and pediatric tumor profiling, eight companion diagnostics (CDx), and additional laboratory developed test (LDT) capabilities. Patient tissue is maximized through simultaneous analysis of DNA and RNA with minimum input of 50 ng. The clinical and analytical validation presented herein demonstrates non-inferiority of MI Cancer Seek relative to other FDA-approved CDx tests (>97% negative and positive percent agreement), as well as its precision, sensitivity, and specificity. Accordingly, MI Cancer Seek represents a safe and effective comprehensive molecular test option supporting biomarker-directed care for oncology patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Caris Life Sciences, Irving, TX 75039, USA.
Zitieren
APA
Domenyuk, V., Benson, K., Carter, P., Magee, D., Zhang, J., Bhardwaj, N., Tae, H., Wacker, J., Rathi, F., Miick, S., Kohli, A., Carroll, J., Cuyugan, L., Perez, E., Zhang, W., Collins, J., Kennedy, P., Ellis, J., Stark, A., …, & Spetzler, D. (2025). Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay. Oncotarget. https://doi.org/10.18632/oncotarget.28761
Vancouver
Domenyuk V, Benson K, Carter P, Magee D, Zhang J, Bhardwaj N, et al. Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay. Oncotarget. 2025. doi:10.18632/oncotarget.28761
BibTeX
@article{Domenyuk2025,
author = {Domenyuk, Valeriy and Benson, Kasey and Carter, Peggy and Magee, Daniel and Zhang, Jian and Bhardwaj, Nitin and Tae, Hongseok and Wacker, James and Rathi, Foram and Miick, Siobhan and Kohli, Aastha and Carroll, Joshua and Cuyugan, Lori and Perez, Evelyn and Zhang, Wayeesha and Collins, John and Kennedy, Patrick and Ellis, Jeremy and Stark, Adam and Loskutov, Andrey and Cuttone, Brittany and Taylor, Blake and Feldman, Rebecca and Swenson, Jeff and Bryant, David and Hahn-Lowry, Robert and Kaushal, Raunaq and Ribeiro, Jennifer R and Abraham, Jim and Radovich, Milan and Sledge, George W and Oberley, Matthew and Spetzler, David},
title = {Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay},
journal = {Oncotarget},
year = {2025},
doi = {10.18632/oncotarget.28761}
}
EUVIMED